RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL

被引：0
|
作者：
Mead, A. [1 ]
Clark, R. [2 ]
Chacko, J. [3 ]
Knapper, S. [4 ]
Yin, J. [5 ]
Milojkovic, D. [6 ]
Farquharson, M. [7 ]
Ali, S. [8 ]
Garg, M. [9 ]
Andrews, C. [10 ]
Dawson, M. Ktiouet [10 ]
Harrison, C. [11 ]
机构：
[1] Univ Oxford, Weatherall Inst Mol Med, MRC, Oxford, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England
[4] Cardiff Univ, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales
[5] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England
[6] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, London, England
[7] Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland
[8] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
[9] Leicester Royal Infirm, Leicester, Leics, England
[10] Novartis Pharmaceut UK, Frimley, Camberley, England
[11] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P414
引用
收藏
页码：131 / 132
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
    Ades, Lionel
    Boehrer, Simone
    Prebet, Thomas
    Beyne-Rauzy, Odile
    Legros, Laurence
    Ravoet, Christophe
    Dreyfus, Francois
    Stamatoullas, Aspasia
    Chaury, Marie Pierre
    Delaunay, Jacques
    Laurent, Guy
    Vey, Norbert
    Burcheri, Sara
    Mbida, Rose-Marie
    Hoarau, Natacha
    Gardin, Claude
    Fenaux, Pierre
    [J]. BLOOD, 2009, 113 (17) : 3947 - 3952
  • [42] Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan
    Hou, Hsin-An
    Lin, Chien-Chin
    Kuo, Ming-Chung
    Lin, Shyuann-Yuh
    Gau, Jyh-Pyng
    Wang, Ming-Chung
    Chang, Ming-Chih
    Chen, Tsung-Chih
    Yeh, Su-Peng
    Chen, Yeu-Chin
    Huang, Cih-En
    Chen, Chieh-Wen
    Lee, Yee-Ming
    Ku, Fan-Chen
    Shih, Lee-Yung
    [J]. BLOOD, 2019, 134
  • [43] COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1-, INTERMEDIATE-2-, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY
    Passamonti, F.
    Gupta, V.
    Martino, B.
    Foltz, L.
    Zaritksey, A.
    Al-Ali, H. K.
    Tavares, R.
    Maffioli, M.
    Raanani, P.
    Giraldo, P.
    Griesshammer, M.
    Bouard, C.
    Ronco, J. Perez
    Tiwari, R.
    Vannucchi, A. M.
    [J]. HAEMATOLOGICA, 2017, 102 : 548 - 548
  • [44] Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Bose, Prithviraj
    Kadia, Tapan
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Daver, Naval
    Estrov, Zeev
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Zhou, Lingsha
    Mak, Po Yee
    Salinas, Karina
    Tuttle, Carla Kay
    Pierce, Sherry
    Popat, Uday
    Verstovsek, Srdan
    [J]. BLOOD, 2017, 130
  • [45] MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
    Bradley, Terrence
    Kuykendall, Andrew
    Komrokji, Rami S.
    Berry, Tymara
    Dougherty, Souria
    Sherman, Laurie
    Peng, Lixian
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Mascarenhas, John
    [J]. BLOOD, 2022, 140 : 3941 - 3942
  • [46] Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
    Gill, Harinder
    Au, Lester
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Leung, Garret Mk
    Lee, Carmen
    Wu, Tony Kwun Yat
    Ngai, Cheong
    Ho, Ryan
    Sin, Albert Chun Fung
    Hou, Hsin-An
    Chen, Chih-Cheng
    Kwong, Yok-Lam
    [J]. BLOOD, 2022, 140 : 1522 - 1522
  • [47] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [48] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [49] Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.
    Pemmaraju, Naveen
    Ali, Haris
    Gupta, Vikas
    Schiller, Gary J.
    Lee, Sangmin
    Yacoub, Abdulraheem
    Talpaz, Moshe
    Wysowskyj, Halyna
    Shemesh, Shay
    Chen, Janice
    Brooks, Christopher
    Poradosu, Enrique
    Rupprecht, Nicole
    Pardanani, Animesh Dev
    Tefferi, Ayalew
    Wang, Eunice S.
    Taparia, Minakshi
    Verstovsek, Srdan
    Khoury, Joseph
    Patnaik, Mrinal Mahesh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study
    Passamonti, Francesco
    Gupta, Vikas
    Martino, Bruno
    Foltz, Lynda
    Zaritskey, Andrey
    Al-Ali, Haifa Kathrin
    Tavares, Renato
    Maffioli, Margherita
    Raanani, Pia
    Giraldo, Pilar
    Griesshammer, Martin
    Guglielmelli, Paola
    Bouard, Catherine
    Paley, Carole
    Tiwari, Ranjan
    Vannucchi, Alessandro M.
    [J]. HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 558 - 566
12345